ClinVar Miner

Submissions for variant NM_005343.4(HRAS):c.520C>T (p.Pro174Ser) (rs397517144)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen RASopathy Variant Curation Expert Panel RCV000520658 SCV000616467 benign Rasopathy 2017-04-18 reviewed by expert panel curation The filtering allele frequency of the c.520C>T (p.Pro174Ser) variant in the HRAS gene is 0.115% (20/11482) of Latino chromosomes by the Exome Aggregation Consortium, which is a high enough frequency to be classified as benign based on thresholds defined by the ClinGen RASopathy Expert Panel (BA1; PMID:29493581)
Fulgent Genetics,Fulgent Genetics RCV000755642 SCV000883040 likely benign Congenital giant melanocytic nevus; Epidermal nevus syndrome; Bladder cancer, somatic; Costello syndrome; Epidermal nevus; Follicular thyroid carcinoma 2018-10-31 criteria provided, single submitter clinical testing
GeneDx RCV000038467 SCV000728563 benign not specified 2017-09-15 criteria provided, single submitter clinical testing This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Integrated Genetics/Laboratory Corporation of America RCV000038467 SCV000917530 benign not specified 2018-12-11 criteria provided, single submitter clinical testing Variant summary: HRAS c.520C>T (p.Pro174Ser) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00023 in 275570 control chromosomes, predominantly at a frequency of 0.0018 within the Latino subpopulation in the gnomAD database. The observed variant frequency within Latino control individuals in the gnomAD database is approximately 720 fold of the estimated maximal expected allele frequency for a pathogenic variant in HRAS causing Noonan Syndrome and Related Conditions phenotype (2.5e-06), strongly suggesting that the variant is a benign polymorphism found primarily in populations of Latino origin. c.520C>T has been reported in the literature in an individual affected with Costello Syndrome, without strong evidence for pathogenicity (Johnson_2014). These report(s) do not provide unequivocal conclusions about association of the variant with Noonan Syndrome and Related Conditions. Three ClinVar submissions including the ClinGen RASopathy Expert Panel, an FDA recognized database cite the variant as likely benign/benign (evaluation after 2014). Based on the evidence outlined above, the variant was classified as benign.
Invitae RCV000234040 SCV000288862 likely benign Costello syndrome 2017-09-29 criteria provided, single submitter clinical testing
Laboratory for Molecular Medicine,Partners HealthCare Personalized Medicine RCV000038467 SCV000062145 uncertain significance not specified 2012-08-10 criteria provided, single submitter clinical testing The Pro174Ser variant in HRAS has not been reported in the literature nor previo usly identified by our laboratory. Functional studies suggest the Pro174Ser vari ant would not significantly impact HRAS signaling (Yong 2011). However, this in vitro assay may not accurately represent biological function. Computational anal yses (biochemical amino acid properties, conservation, AlignGVGD, PolyPhen2, and SIFT) do not provide strong support for or against an impact to the protein. In summary, additional information is needed to fully assess the clinical signific ance of the Pro174Ser variant.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.